Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long-Term Growth
TipRanks (Fri, 5-Jun 12:34 PM ET)
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
Business Wire (Thu, 4-Jun 8:58 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
PRNewswire (Thu, 4-Jun 10:08 AM ET)
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Globe Newswire (Thu, 4-Jun 7:30 AM ET)
Globe Newswire (Thu, 4-Jun 1:00 AM ET)
Globe Newswire (Wed, 3-Jun 7:30 AM ET)
Globe Newswire (Mon, 1-Jun 1:30 AM ET)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Business Wire (Thu, 28-May 4:01 PM ET)
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
PRNewswire (Fri, 22-May 9:00 AM ET)
Globe Newswire (Thu, 21-May 6:00 PM ET)
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen trades on the NASDAQ stock market under the symbol BIIB.
As of June 8, 2026, BIIB stock price declined to $192.62 with 978,614 million shares trading.
BIIB has a beta of 0.58, meaning it tends to be less sensitive to market movements. BIIB has a correlation of 0.04 to the broad based SPY ETF.
BIIB has a market cap of $28.44 billion. This is considered a Large Cap stock.
Last quarter Biogen reported $2 billion in Revenue and $3.57 earnings per share. This beat revenue expectation by $230 million and exceeded earnings estimates by $.62.
In the last 3 years, BIIB traded as high as $319.76 and as low as $110.04.
The top ETF exchange traded funds that BIIB belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BIIB has outperformed the market in the last year with a price return of +47.8% while the SPY ETF gained +25.9%. However, in the short term, BIIB had mixed performance relative to the market. It has underperformed in the last 3 months, returning +2.4% vs +8.8% return in SPY. But in the last 2 weeks, BIIB shares have fared better than the market returning -0.6% compared to SPY -0.9%.
BIIB support price is $191.38 and resistance is $199.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIIB shares will trade within this expected range on the day.
